Hjem › Kardiovaskulær sykdom › California › Los Angeles
Kliniske studier for Kardiovaskulær sykdom i Los Angeles, CA
18 studier for Kardiovaskulær sykdom søker deltakere på steder i og rundt Los Angeles (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Product Surveillance Registry
RekruttererObservasjonsstudie
- Los Angeles, Los Angeles
Zenith® Fenestrated+ Clinical Study
Rekrutterer
- University of Southern California, Los Angeles
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Rekrutterer
- PIH Health Good Samaritan Hospital, Los Angeles
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Keck Hospital of the University of Southern California, USC, Los Angeles
- og 1 flere
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Rekrutterer
- Cedars-Sinai Medical Center, Los Angeles
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
RekruttererFase 3
- Keck Medical Center USC, Los Angeles
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RekruttererFase 4Frivillige helsepersonell ønskes velkommen
- Cedars-Sinai Medical Center, Los Angeles
- VA Greater Los Angeles, Los Angeles
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RekruttererFase 3
- Research Site, Los Angeles
- Research Site, Los Angeles
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RekruttererFase 3
- InvivoCure, Los Angeles
WISE CVD - Continuation (WISE HFpEF)
RekruttererObservasjonsstudie
- Cedars-Sinai Women's Heart Center, Los Angeles
Global Paradise System US Post Approval Study
RekruttererObservasjonsstudie
- Cedars-Sinai Medical Center, Los Angeles
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Rekrutterer
- USC, Los Angeles
Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History
Rekrutterer
- Keck School of Medicine, University of Southern California, Los Angeles
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Rekrutterer
- Keck School of Medicine of USC, Los Angeles
- UCLA Medical Center, Los Angeles
CANF-Comb-II PET-MR in Atherosclerosis Multisite
RekruttererObservasjonsstudie
- Cedars Sinai Medical Center, Los Angeles
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RekruttererFase 2
- UCLA Center for Clinical AIDS Research and Education (CARE), Los Angeles
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
Rekrutterer
- Cedars-Sinai Medical Center, Los Angeles
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
Rekrutterer
- Cedars - Sinai Medical Center, Los Angeles
PARTNER 3 Trial - Aortic Valve-in-Valve
Rekrutterer
- University of California Los Angeles, Los Angeles
Kardiovaskulær sykdom-studier i andre byer
- Boston, MA37 studier
- New York City, NY33 studier
- Washington, DC28 studier
- Houston, TX24 studier
- Dallas, TX23 studier
- Atlanta, GA22 studier
- Cleveland, OH22 studier
- Chicago, IL21 studier
- Philadelphia, PA21 studier
- Pittsburgh, PA20 studier
- St. Louis, MO20 studier
- Nashville, TN18 studier
Andre studier i Los Angeles
- Ikke-småcellet lungekreft87 studier
- Kreft (alle typer)74 studier
- Brystkreft73 studier
- Prostatakreft61 studier
- Kolorektal kreft59 studier
- Metastatisk kreft57 studier
- Eggstokkreft50 studier
- Lungekreft45 studier
- Plateepitelcancer i hode og hals42 studier
- Pankreaskreft35 studier
- Endometriekreft34 studier
- Melanom34 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.